HeartBeam, Inc. (BEAT) |
| 0.3929 -0.009 (-2.22%) 10-14 16:00 |
| Open: | 0.4085 |
| High: | 0.4099 |
| Low: | 0.38 |
| Volume: | 987,409 |
| Market Cap: | 22(M) |
| PE Ratio: | -0.77 |
| Exchange: | NASDAQ |
| Industry: | Medical - Specialties |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 0.95 |
| Resistance 1: | 0.72 |
| Pivot price: | 0.44 |
| Support 1: | 0.35 |
| Support 2: | 0.30 |
| 52w High: | 4 |
| 52w Low: | 0.355 |
HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.
Financials
| EPS | -0.500 |
| Book Value | 0.140 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -153.5 |
| Return on Equity (ttm) | -328.4 |
Company news
Fri, 09 Oct 2026
HeartBeam (BEAT) grants Ferrari 90,625 special stock units tied to suspended cash retainers. - Stock Titan
Fri, 09 Oct 2026
A 37,500-unit special award at HeartBeam (BEAT) accompanies suspended July–December 2026 cash retainers. - Stock Titan
Fri, 09 Oct 2026
A director receives a 93,750-share option at $0.435 per share from HeartBeam (BEAT). - Stock Titan
Tue, 06 Oct 2026
HeartBeam (NasdaqCM:BEAT) Stock Forecast & Analyst Predictions - Simply Wall Street
Mon, 05 Oct 2026
HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment - Business Wire
Mon, 21 Sep 2026
HeartBeam, Inc. Letter to Shareholders - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
